Listen to this article · 6 min listen

The healthcare AI market, once swimming in cash and big numbers, just went through a painful correction. The story of Olive AI is a lesson for everyone, investors and founders alike: a good story only gets you so far, but eventually you need hard proof. This study looks at the money trail from a peak valuation to a total shutdown, comparing it to a different company that focused on published results, which shows why having solid evidence is so important in a market that’s getting a lot pickier.

The Collapse of Unproven Automation

Olive AI looked like it was going to change everything for hospital administration. It attracted investors, raising around $900 million and hitting a peak valuation of $4 billion. A lot of that cash, especially during its growth phase, came from big names like Tiger Global, all funding a plan for major efficiency in complex healthcare operations. The idea was simple: AI would take over annoying tasks like prior authorizations, claims processing, and revenue cycle management, which was supposed to save struggling hospital systems a ton of money. But even with all that capital, Olive AI completely shut down in October 2023. What was missing? It failed because it had no peer-reviewed evidence showing it actually produced the financial outcomes it promised. The money poured in and the valuation shot up, but there was never any independent, rigorous measurement of its real impact on hospital economics. All that cash was backing an automation tool without a clear, validated financial return, a mistake that turned out to be fatal when the investment mood changed.

A Cautionary Tale: Teladoc/Livongo and the Price of Unproven Value

Olive AI isn’t alone. Its failure puts it in the same category as the Teladoc/Livongo merger aftermath. Both situations show the danger of growing your business without first building a foundation of proven, peer-reviewed value. The Teladoc/Livongo merger which was aimed at creating a complete digital health company, also couldn’t really explain or show the financial benefits of the combination in a way that satisfied the market. The stock got hammered, which proved that a good strategy and big market share aren’t enough if you can’t show a clear, validated financial return. In both cases, the investment was all about getting big and grabbing market share, not about generating a verifiable ROI. For Olive AI, the goal was to get its tools into as many hospitals as possible, instead of carefully proving the financial benefits for each customer with peer-reviewed studies. That strategy worked for attracting early money in a hot market, but it left the company exposed when investors stopped rewarding speculative growth and started demanding real, evidence-based returns.

A Different Playbook: Hinge Health’s Evidence-First Strategy

During the same time Olive AI was growing based on an unproven promise, Hinge Health took the opposite path. As a digital musculoskeletal solution provider, instead of pushing for fast, unmeasured growth, Hinge Health focused on building a solid record of published outcomes long before it ever thought about going public. This meant spending real money on clinical trials, real-world evidence studies, and getting articles into peer-reviewed journals that showed clear improvements in patient health and (just as important) big cost savings for employers and health plans. Hinge Health peer-reviewed outcome studies This decision to build an evidence base first really paid off. While Olive AI was shutting its doors, Hinge Health had its NYSE listing in May 2025, supported by its long track record of verifiable results. Their success offers a key lesson: for any healthcare AI tool, especially one that claims a high ROI, demonstrable financial outcomes are a basic requirement for growth and investor trust. The market’s willingness to bet on unverified promises has dried up. Now, there’s a demand for the kind of hard data that Hello Heart provides with its peer-reviewed $1,709 per-member savings and 47% reduction in inpatient stays.

Measuring ROI is the New Reality

The change in the funding world between 2021 and 2023 was a massive repricing of the entire healthcare AI category. In 2021, capital grew faster than evidence, rewarding good stories and huge projected market sizes (TAM). By 2023, the market valued provable ROI more. This repricing, which you can also see in the post-merger assessment of Teladoc/Livongo, shows the growing need for measuring healthcare AI ROI with academic discipline. For anyone investing in or building a healthcare company, the Olive AI story is a clear lesson in the need for evidence. Capital markets now demand validated financial outcomes, not just promises of future efficiency. So what does that mean in practice? It requires a clear framework for measuring ROI that relies on independently published outcomes, not just vendor-supplied projections. Investors are now using public sources like the SEC EDGAR database, PubMed scientific literature database, and Health Affairs journal to check the proof behind AI company claims. The best ROI use cases in healthcare AI will be the ones that can clearly and rigorously show their financial impact. Companies have to invest in explaining their methodology, conducting real employer cost-savings case studies, and getting their claims validated by peer review. The days of unverified automation getting top-tier funding are over. Success in healthcare AI now requires a measurable, verifiable, and independently validated return on investment. Every AI health company is now judged by this result: scaling without an evidence base risks a complete shutdown, not just slower growth.

Frequently Asked Questions

What was the primary reason for Olive AI’s failure despite significant funding?

Olive AI failed primarily due to the critical absence of a peer-reviewed evidence base demonstrating its promised financial outcomes. Despite raising substantial capital and achieving a high valuation, it lacked independently validated documentation of its return on investment (ROI) for healthcare unit economics, which proved fatal in a shifting investment climate.

How did Olive AI’s approach to market differ from successful companies like Hinge Health?

Olive AI prioritized rapid, unmeasured deployment and scaling without meticulously proving financial uplift through peer-reviewed studies. In contrast, Hinge Health meticulously built a published outcomes record through clinical trials, real-world evidence studies, and peer-reviewed publications, demonstrating clear, measurable improvements and cost savings before seeking public listing.

What is the key lesson for healthcare AI companies regarding evidence discipline?

The key lesson is that for healthcare AI applications, particularly those aiming for high ROI use cases, demonstrable financial outcomes are a foundational requirement for sustainable growth and investor confidence. The market now demands independently validated financial outcomes and rigorous data, moving beyond vendor-claimed projections to independently published results.

What does the market now demand from healthcare AI companies in terms of ROI?

The market now demands independently validated financial outcomes and rigorous data, moving beyond vendor-claimed projections to independently published financial outcomes. Investors are no longer content with promises of future efficiency but require demonstrable ROI measured with academic rigor.